share_log

Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target

Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target

Needham重申买入蓝图药品,维持97美元的目标股价
Benzinga ·  04/26 05:35

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.

尼德姆分析师阿米·法迪亚重申Blueprint Medicines(纳斯达克股票代码:BPMC)的买入并维持97美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发